{
  "nct_id": "NCT06549595",
  "age": "Adults",
  "cancer_center_accrual_goal_upper": 0,
  "curated_on": "2024-08-12",
  "study_start_date": "2024-08-07",
  "study_completion_date": "",
  "data_table4": "Interventional",
  "drug_list": {
    "drug": [
      {
        "drug_name": "Drug: BR"
      },
      {
        "drug_name": "Drug: R-CVP"
      },
      {
        "drug_name": "Drug: R-CHOP"
      },
      {
        "drug_name": "Drug: AZD0486"
      }
    ]
  },
  "long_title": "A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 Plus Rituximab Versus Chemotherapy Plus Rituximab in Previously Untreated Participants With Follicular Lymphoma (SOUNDTRACK-F1)",
  "last_updated": "2025-08-14",
  "management_group_list": {
    "management_group": [
      {
        "is_primary": "Y",
        "management_group_name": "Group1"
      }
    ]
  },
  "oncology_group_list": {
    "oncology_group": [
      {
        "group_name": "Group1",
        "is_primary": "N"
      }
    ]
  },
  "phase": "PHASE3",
  "principal_investigator": "Chan Cheah, MBBS FRACP FRCPA DMSc",
  "principal_investigator_institution": "Sir Charles Gairdner Hospital (SCGH)",
  "program_area_list": {
    "program_area": [
      {
        "is_primary": "Y",
        "program_area_name": "Program1"
      }
    ]
  },
  "protocol_id": 0,
  "protocol_ids": [],
  "protocol_no": "",
  "protocol_target_accrual": 1015,
  "protocol_type": "INTERVENTIONAL",
  "prior_treatment_requirements": [
    "Inclusion Criteria:",
    "1. Participant must be at least 18 years of age, inclusive, at the time of signing the ICF.",
    "2. Histologically confirmed diagnosis of classic FL per WHO 2022 classification",
    "3. ECOG performance status of 0 to 2",
    "4. No prior systemic lymphoma-directed therapy",
    "5. Need for systemic treatment meeting at least 1 GELF criteria",
    "6. FDG-avid and measurable disease",
    "7. Stage II to IV and FLIPI 2-5 \\[Phase III only\\]",
    "8. Adequate liver, hematological, renal and cardiac function.",
    "The above is a summary, other inclusion criteria details may apply",
    "Exclude - Exclusion Criteria:",
    "Exclude - 1. Follicular large B-cell lymphoma (WHO 2022 classification), formerly Follicular lymphoma Grade 3B (WHO 2016 classification) or suspicion for histologic transformation to high-grade/aggressive lymphoma",
    "Exclude - 2. Contra-indication to BR, RCVP, and R-CHOP",
    "Exclude - 3. Participants with or history of CNS lymphoma",
    "Exclude - 4. Presence of \\>5000 circulating lymphoma cells",
    "Exclude - 5. Active or uncontrolled infection requiring systemic therapy and which places participant at unacceptable risk if he/she were to participate in the study",
    "Exclude - The above is a summary, other exclusion criteria details may apply"
  ],
  "short_title": "A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients",
  "site_list": {
    "site": []
  },
  "sponsor_list": {
    "sponsor": [
      {
        "is_principal_sponsor": "Y",
        "sponsor_name": "AstraZeneca",
        "sponsor_protocol_no": "",
        "sponsor_roles": "sponsor"
      }
    ]
  },
  "staff_list": {
    "protocol_staff": []
  },
  "status": "open to accrual",
  "summary": "This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the AZD0486 plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.",
  "treatment_list": {
    "step": [
      {
        "step_internal_id": 111,
        "step_code": "1",
        "step_type": "Registration",
        "arm": [
          {
            "arm_code": "Rituximab, AZD0486 - A",
            "arm_internal_id": 0,
            "arm_description": "AZD0486 regimen A plus rituximab",
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "0",
                "level_description": "Drug: AZD0486",
                "level_internal_id": 0,
                "level_suspended": "N"
              }
            ]
          },
          {
            "arm_code": "Rituximab, AZD0486 - B",
            "arm_internal_id": 1,
            "arm_description": "AZD0486 regimen B plus rituximab",
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "0",
                "level_description": "Drug: AZD0486",
                "level_internal_id": 0,
                "level_suspended": "N"
              }
            ]
          },
          {
            "arm_code": "Chemoimmunotherapy",
            "arm_internal_id": 2,
            "arm_description": "Investigator's choice between 3 standard immunochemotherapy regimen (R-CHOP or R-CVP followed by rituximab maintenance, or B-R followed by rituximab maintenance)",
            "arm_suspended": "N",
            "dose_level": [
              {
                "level_code": "0",
                "level_description": "Drug: R-CHOP",
                "level_internal_id": 0,
                "level_suspended": "N"
              },
              {
                "level_code": "1",
                "level_description": "Drug: R-CVP",
                "level_internal_id": 1,
                "level_suspended": "N"
              },
              {
                "level_code": "2",
                "level_description": "Drug: BR",
                "level_internal_id": 2,
                "level_suspended": "N"
              }
            ]
          }
        ],
        "match": [
          {
            "clinical": {
              "age_numerical": ">=18",
              "disease_status": [
                "Advanced"
              ],
              "oncotree_primary_diagnosis": "Lymphoid Neoplasm"
            }
          }
        ]
      }
    ]
  }
}